Skip to main content
SpringerLink
Log in

Exfoliating and Necrotizing Soft Tissue Diseases

  • Chapter
  • First Online:
Burn Care for General Surgeons and General Practitioners

  • 1418 Accesses

Abstract

Burn centers are often called upon to manage skin diseases other than burn injuries. These diseases are typically exfoliating skin diseases such toxic epidermal necrolysis syndrome and Stevens–Johnson syndrome, and necrotizing skin diseases such as necrotizing soft tissue infections, necrotizing fasciitis, and purpura fulminans. The unifying characteristic of these diseases is skin and soft tissue compromise and thus these patients are best managed in burn centers with expertise in wound care. This chapter reviews the etiology, pathogenesis, clinical manifestations, and treatment options for these diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stevens AMJ, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: a report of two cases in children. Am J Dis Child. 1922;24:526–33.

    Article  Google Scholar 

  2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68(11):355–61.

    Article  CAS  PubMed  Google Scholar 

  3. Roujeau JC et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New Engl J Med. 1995;333(24):1600–7.

    Article  CAS  PubMed  Google Scholar 

  4. Lissia M et al. Toxic epidermal necrolysis (Lyell’s disease). Burns. 2010;36(2):152–63.

    Article  PubMed  Google Scholar 

  5. Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res. 2008;29(5):706–12.

    Article  PubMed  Google Scholar 

  6. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma, Immunol. 2006;97(3):272–80. quiz 281–3.

    Article  CAS  Google Scholar 

  7. Letko E et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94(4):419–36. quiz 436–8.

    Article  PubMed  Google Scholar 

  8. Weinand C et al. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns. 2013;39(7):1449–55.

    Article  CAS  PubMed  Google Scholar 

  9. Peppercorn AF et al. High-level human herpesvirus-6 viremia associated with onset of Stevens-Johnson syndrome: report of two cases. J Burn Care Res. 2010;31(2):365–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Hung S-I et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16(4):297–306.

    Article  CAS  PubMed  Google Scholar 

  11. Hung SI et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–9. Erratum appears in Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Borchers AT et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev. 2008;7(8):598–605.

    Article  CAS  PubMed  Google Scholar 

  13. Correia O et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol. 2002;47(1):58–62.

    Article  PubMed  Google Scholar 

  14. Chave TA et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241–53.

    Article  CAS  PubMed  Google Scholar 

  15. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181–200.

    Article  PubMed  Google Scholar 

  16. Mofid MZ et al. Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil. 2000;21(3): 246–7.

    Article  CAS  PubMed  Google Scholar 

  17. Goyal S et al. Toxic epidermal necrolysis in children: medical, surgical, and ophthalmologic considerations. J Burn Care Res. 2009;30(3):437–49.

    Article  PubMed  Google Scholar 

  18. Palmieri TL et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23(2):87–96.

    Article  CAS  PubMed  Google Scholar 

  19. Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31(1):100–4.

    Article  PubMed  Google Scholar 

  20. Coban YK, Erbatur S, Aytekin AH. A useful combination in the treatment of toxic epidermal necrolysis: octenoidine dihydrocholoride solution and Aquacel-Ag. Burns. 2011;37(3):545–6.

    Article  PubMed  Google Scholar 

  21. Lindford AJ et al. Comparison of Suprathel and allograft skin in the treatment of a severe case of toxic epidermal necrolysis. Burns. 2011;37(7):e67–72.

    Article  PubMed  Google Scholar 

  22. Ng RWM, Cheng YL. Calcium alginate dressing-related hypercalcemia. J Burn Care Res. 2007;28(1): 203–4.

    Article  PubMed  Google Scholar 

  23. Boorboor P et al. Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns. 2008;34(4):487–92.

    Article  CAS  PubMed  Google Scholar 

  24. Huang S-H et al. AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN). Burns. 2008;34(1): 63–6.

    Article  CAS  PubMed  Google Scholar 

  25. Huang S-H et al. Aquacel Ag with Vaseline gauze in the management of toxic epidermal necrolysis (TEN). Burns. 2010;36(1):121–6.

    Article  PubMed  Google Scholar 

  26. Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res. 2008;29(1):269–76.

    PubMed  Google Scholar 

  27. Mosier MJ, DeChristopher PJ, Gamelli RL. Use of therapeutic plasma exchange in the burn unit: a review of the literature. J Burn Care Res. 2013;34(3):289–98.

    Article  PubMed  Google Scholar 

  28. Stella M et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33(4):452–9.

    Article  PubMed  Google Scholar 

  29. Lin A et al. Management of ocular conditions in the burn unit: thermal and chemical burns and Stevens-Johnson syndrome/toxic epidermal necrolysis. J Burn Care Res. 2011;32(5):547–60.

    Article  PubMed  Google Scholar 

  30. Oplatek A et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27(1):26–33.

    Article  PubMed  Google Scholar 

  31. Hii BW et al. Hospital management and clinical factors associated with ophthalmic involvement in toxic epidermal necrolysis. Burns. 2014;40(5):903–8.

    Article  PubMed  Google Scholar 

  32. Bastuji-Garin S et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.

    Article  CAS  PubMed  Google Scholar 

  33. Zhu QY et al. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res. 2012;33(6):e295–308.

    Article  PubMed  Google Scholar 

  34. Sekula P et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32(2):237–45.

    Article  PubMed  Google Scholar 

  35. Cartotto R et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008;29(1): 141–6.

    PubMed  Google Scholar 

  36. Imahara SD et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006;27(3):270–5.

    Article  PubMed  Google Scholar 

  37. Haywood CT, McGeer A, Low DE. Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg. 1999;103(6):1567–73.

    Article  CAS  PubMed  Google Scholar 

  38. Patino JF, Castro D. Necrotizing lesions of soft tissues: a review. World J Surg. 1991;15(2):235–9.

    Article  CAS  PubMed  Google Scholar 

  39. Caruso DM, Foster KN, Chellappan A. Burn center treatment of necrotizing soft tissue infections: necrotizing fasciitis, Fournier’s gangrene, and purpura fulminans. Probl Gen Surg. 2003;20(1):138–45.

    Article  Google Scholar 

  40. Endorf FW, Cancio LC, Klein MB. Necrotizing soft-tissue infections: clinical guidelines. J Burn Care Res. 2009;30(5):769–75.

    Article  PubMed  Google Scholar 

  41. Wall DB et al. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg. 2000;191(3):227–31.

    Article  CAS  PubMed  Google Scholar 

  42. Wong C-H et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg. 2003;85-A(8):1454–60.

    PubMed  Google Scholar 

  43. Wong C-H, Wang Y-S. The diagnosis of necrotizing fasciitis. Curr Opin Infect Dis. 2005;18(2):101–6.

    Article  PubMed  Google Scholar 

  44. Endorf FW et al. Necrotizing soft-tissue infections: differences in patients treated at burn centers and non-burn centers. J Burn Care Res. 2008;29(6):933–8.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Endorf FW, Supple KG, Gamelli RL. The evolving characteristics and care of necrotizing soft-tissue infections. Burns. 2005;31(3):269–73.

    Article  PubMed  Google Scholar 

  46. Bernal NP et al. Trends in 393 necrotizing acute soft tissue infection patients 2000-2008. Burns. 2012; 38(2):252–60.

    Article  PubMed  Google Scholar 

  47. Pham TN et al. Assessment of functional limitation after necrotizing soft tissue infection. J Burn Care Res. 2009;30(2):301–6.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Pikturnaite J, Soldin M. Impact of necrotising fasciitis on quality of life: a qualitative analysis. Burns. 2014;40(5):848–51.

    Article  PubMed  Google Scholar 

  49. Francis KR et al. Implications of risk factors in necrotizing fasciitis. Am Surg. 1993;59(5):304–8.

    CAS  PubMed  Google Scholar 

  50. Adcock DM, Brozna J, Marlar RA. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis. Semin Thromb Hemost. 1990;16(4):333–40.

    Article  CAS  PubMed  Google Scholar 

  51. Chasan PE, Hansbrough JF, Cooper ML. Management of cutaneous manifestations of extensive purpura fulminans in a burn unit. J Burn Care Rehabil. 1992;13(4):410–3.

    Article  CAS  PubMed  Google Scholar 

  52. Adcock DM, Hicks MJ. Dermatopathology of skin necrosis associated with purpura fulminans. Semin Thromb Hemost. 1990;16(4):283–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Arizona Burn Center at Maricopa Integrated Health System, 2601 E Roosevelt, Phoenix, AZ, 85008, USA

    Kevin N. Foster M.D., M.B.A., F.A.C.S.

Authors
  1. Kevin N. Foster M.D., M.B.A., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin N. Foster M.D., M.B.A., F.A.C.S. .

Editor information

Editors and Affiliations

  1. Univ. of California, Davis Med. Center, Shriners Hosp for Children N California, Sacramento, California, USA

    David G. Greenhalgh

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Foster, K.N. (2016). Exfoliating and Necrotizing Soft Tissue Diseases. In: Greenhalgh, D. (eds) Burn Care for General Surgeons and General Practitioners . Springer, Cham. https://doi.org/10.1007/978-3-319-29161-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29161-1_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-29159-8

  • Online ISBN: 978-3-319-29161-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation